Transitioning from Chemoimmunotherapy to More Targeted Approaches in MCL

Course Description

The natural history of mantle cell lymphoma (MCL) is a repeated pattern of remission and relapse; after a few relapses, patients have a very small chance of responding to any therapy. Considerable progress has been made over the last decade as the treatment paradigm has shifted from traditional chemoimmunotherapy toward targeted and cell-based therapies in both the frontline and relapsed/refractory (R/R) settings. However, selecting the best treatment is often complicated, involving multiple patient factors, and there is no established standard of care.

During Transitioning from Chemoimmunotherapy to More Targeted Approaches in MCL, experts discuss using prognostic tools to plan treatment for individuals with MCL and targetable mutations, integrating emerging data and guidelines recommendations for front-line treatment, potential benefits and risks of chemotherapy-free targeted options, planning safe and effective use of novel therapies and combinations in the second- and third-line settings and for R/R MCL, and eradicating health inequities and closing the survival gap.

This taped Satellite Symposium was derived from the Society of Hematologic Oncology 2022 Annual Meeting.

Other Courses in this Series

Other Courses That May be of Interest